Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Lineage Cell Therapeutics, Inc. < Previous 1 2 3 Next > Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer July 24, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index May 22, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update May 11, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) May 09, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 May 04, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update March 09, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 March 02, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration April 26, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update November 10, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage to Present at 2023 AAPS National Biotechnology Conference April 18, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022 November 03, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium March 30, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells October 10, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit March 20, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D. March 06, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications February 22, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa October 04, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss February 08, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference August 15, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference November 29, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update August 11, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration November 28, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022 August 04, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer October 31, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology June 02, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel October 03, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update May 12, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022 May 05, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration May 03, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022 April 26, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.